|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent No. 8,580,293
Summary
U.S. Patent No. 8,580,293, granted on November 12, 2013, to AbbVie Inc., covers a specific class of immunomodulatory compounds derived from thalidomide and lenalidomide structures. The patent primarily aims to secure intellectual property rights over novel derivatives with enhanced therapeutic profiles, particularly in treating diseases such as multiple myeloma, inflammatory conditions, and certain cancers.
The patent’s claims extend to chemical entities, methods of use, and preparation processes, with emphasis on structural modifications that improve efficacy, selectivity, and pharmacokinetics. The patent landscape surrounding this patent is characterized by a proliferation of follow-on patents, including both chemical composition claims and methods of treatment, reflecting its strategic importance in multiple sclerosis (MS), oncology, and immunomodulation therapeutics.
This analysis provides a comprehensive review of the patent's scope, claims, and its position within the broader patent landscape.
1. Scope of the Patent
1.1. Chemical Structure and Derivative Scope
U.S. Patent No. 8,580,293 claims a class of compounds characterized by a core thalidomide or lenalidomide backbone, with specific substitutions designed to modulate biological activity.
Key features include:
| Structural Elements |
Specifics |
| Core structure |
Thalidomide or lenalidomide derivatives |
| Substituents |
Heterocyclic groups at the N-atom, aromatic or aliphatic groups at the C-atom, or linked to the phthaloyl ring |
| Functional group variations |
Methoxy, amino, or hydroxy groups to enhance solubility and activity |
The scope extends to considerable variations within these structural parameters, effectively covering a broad chemical space.
1.2. Therapeutic and Methodological Scope
-
Indications: The patent broadly claims methods of treating conditions mediated by immunomodulation, including multiple myeloma, psoriasis, rheumatoid arthritis, and other inflammatory or neoplastic diseases.
-
Methods of Use: Claims include the administration of the claimed compounds, alone or in combination with other agents, for specific conditions, emphasizing methods of treatment rather than mere compound use.
-
Preparation Processes: Claims encompass synthesis routes enabling efficient production of these derivatives, optimizing for purity and yield.
2. Critical Analysis of Core Claims
2.1. Claim Structure Overview
| Claim Type |
Description |
Number of Claims |
Key Elements |
| Composition Claims |
Chemical compounds encompassed by the class |
20+ |
Structural variations, specific substitutions |
| Method of Treatment Claims |
Use of compounds for treating designated diseases |
10+ |
Disease targets, administration modes |
| Process Claims |
Synthesis methods for making compounds |
5+ |
Starting materials, reaction steps |
2.2. Claim Language and Limitations
- Claims are articulated with a combination of Markush structures, enabling broad coverage.
- Limitations often hinge on specific substitutions within the structural core, which narrows claims but still maintains significant breadth.
- The use of claim-dependent language emphasizes specific derivatives while referencing broader classes for coverage.
2.3. Potential Patent Thickets and Freedom-to-Operate
- The broad chemical and therapeutic claims intersect with multiple prior art references, including patents owned by Celgene, Johnson & Johnson, and other entities.
- Patent thickets exist around subclasses of immunomodulators leveraging thalidomide derivatives and their use in disease treatment, necessitating careful freedom-to-operate analysis.
3. Patent Landscape Analysis
3.1. Key Related Patents and Patent Families
| Patent Number |
Owner |
Focus |
Filing Date |
Relevance |
| US 7,829,241 |
Celgene |
Thalidomide analogs for cancer and inflammation |
2006 |
Precedent, foundational for thalidomide derivative patents |
| US 8,498,452 |
Celgene |
Nitrogen-substituted thalidomide derivatives |
2005 |
Overlapping chemical space, potential infringement considerations |
| WO 2012092217 |
Celgene/Inventors |
Methods of making thalidomide derivatives |
2011 |
Synthesis routes complementing the '293 patent claims |
3.2. Main Competitors and Patent Holders
| Entity |
Patent Rights Focus |
Strategic Position |
| AbbVie |
Immunomodulatory derivatives; methods |
Extensive claims in treatment of multiple myeloma and inflammation |
| Celgene |
Thalidomide-based compounds; synthesis methodologies |
Core patents affecting generics and biosimilars |
| Janssen |
Related IMiDs, derivative compositions |
Competing compounds with overlapping claims |
3.3. Patent Filing Trends and Publications
- The patent family includes applications filed globally (PCT filings from 2010-2012), reflecting strategic expansion.
- Follow-on patent applications include efforts to cover specific derivatives, methods of synthesis, and treatment strategies.
- Recent years show increased activity around combination therapies and novel substituents, indicating ongoing innovation.
4. Comparison with Other Key Patents
| Aspect |
U.S. Patent 8,580,293 |
Celgene US 7,829,241 |
Johnson & Johnson US 8,991,720 |
| Scope of Chemical Entities |
Broad class of thalidomide derivatives |
Specific derivatives, including amino-modified analogs |
Focus on novel derivatives and uses |
| Therapeutic Claims |
Multiple myeloma, inflammation |
Multiple cancers, immune disorders |
Multiple myeloma, lymphoma |
| Patent Term Expiry |
2030 (estimated, considering 20-year term) |
2024 (prior art) |
2032 (pending expiration) |
| Geographical Coverage |
US focus; international equivalents filed |
US and international patents |
US, Europe, Japan |
5. Implications for Drug Development and Commercialization
- The patent’s broad chemical and therapeutic claims provide extensive freedom-to-operate, but overlapping rights with existing patents warrant careful analysis.
- The structure-activity relationship (SAR) claims signal a focused avenue for developing next-generation derivatives.
- The patent landscape indicates active patenting, requiring strategic licensing or design-around.
6. Advantages and Limitations of the Patent
Advantages:
| Benefit |
Explanation |
| Broad chemical coverage |
Encompasses many derivatives within the asserted class |
| Established therapeutic scope |
Applicable to multiple diseases, increasing market potential |
| Method claims |
Covers synthesis and treatment methods, broadening enforceability |
Limitations:
| Limitation |
Explanation |
| Potential prior art |
Overlaps with earlier patents, such as Celgene’s IP |
| Structural limitations |
Specific substitutions narrow claims but limit scope |
| Patent term considerations |
Expiry dates, especially for core compounds approaching 2024-2025 |
7. Strategic Recommendations
- Patent clearance: Conduct comprehensive freedom-to-operate analyses, especially regarding prior art by Celgene and Johnson & Johnson.
- Derivative development: Innovate within claim boundaries, focusing on structurally divergent analogs.
- Licensing considerations: Explore licensing opportunities for claims overlapping with other patents.
- Regulatory pathway: Leverage the broad method claims to expedite clinical approval strategies.
8. Key Takeaways
- U.S. Patent 8,580,293’s broad claims cover a significant class of immunomodulatory derivatives with therapeutic relevance.
- The patent landscape is highly active, particularly among major pharmaceutical firms focusing on thalidomide analogs.
- Competitors must analyze overlapping patents, especially prior art from Celgene, to avoid infringement.
- Focused innovation on structurally distinct derivatives may provide avenues for around claims or new patent filings.
- The patent offers strategic advantages in developing new treatments for multiple myeloma, inflammation, and autoimmune diseases, but expiry timelines and overlapping IP must be carefully managed.
FAQs
Q1: What is the primary innovation claimed in U.S. Patent 8,580,293?
A: The patent claims a broad class of thalidomide and lenalidomide derivatives with specific structural modifications designed to enhance therapeutic profiles, notably in immunomodulation and cancer treatment.
Q2: How does this patent relate to prior intellectual property?
A: It builds upon earlier patents (e.g., Celgene’s IP) by claiming a broader chemical class and novel substitutions, but overlaps exist, necessitating detailed freedom-to-operate analysis.
Q3: What diseases are targeted through the methods claimed in this patent?
A: The patent claims methods for treating diseases such as multiple myeloma, psoriasis, rheumatoid arthritis, and certain cancers—all mediated by immune modulation.
Q4: Are there limitations to the breadth of the patent’s claims?
A: Yes. Although broad, the claims are constrained by specific structural features and substitutions, which narrow the scope relative to the entire chemical space of immunomodulatory agents.
Q5: When are the key patent expiration dates, and what is their strategic significance?
A: Estimated initially to expire around 2030, with specific core compound claims possibly expiring sooner (around 2024-2025). These dates influence patent lifecycle management and competitor planning.
References
- U.S. Patent No. 8,580,293. AbbVie Inc.. (2013).
- Celgene Corporation. US 7,829,241. (2010).
- Celgene Corporation. US 8,498,452. (2013).
- World Patent Application WO 2012092217. (2012).
- Recent market filings and patent filings, PatentScope, WIPO. (2022).
More… ↓
⤷ Start Trial
|
